Clinical Trial Update: The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of everolimus (Rad001) and rituximab in patients with Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Everolimus (everolimus)
• Rituximab (rituximab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Non-Hodgkin's Lymphomas | Phase 1 | Status: COMPLETED